Results 101 to 110 of about 28,689 (318)

Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome presenting as aseptic pustular dermatosis: A rare clinical manifestation

Arthritis &Rheumatology, Accepted Article.
Peter Chen, Héloïse Briançon, Deborah Eshagh, Tali‐Anne Szwebel, Pierre Sohier, Rudy Birsen, Benjamin Terrier   +6 more
wiley   +1 more source

Pilot Study of Tildrakizumab in the Treatment of Stable Non‐Segmental Vitiligo

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Treatment for vitiligo is limited, with variable efficacy, and can be time‐consuming or expensive. Recent developments within biologic therapy have demonstrated promising results with managing chronic autoimmune conditions. Objectives To evaluate the efficacy of tildrakizumab in inducing repigmentation in vitiligo.
Henry Lee, Timothy L. Cowan, Cheng Huang, Anna Wilson, Ben Koszegi, Corey Stone, Jade Ng, Sera Sarsam, Hossein Akbarialiabad, Joslin S. Johal, Oliver G. C. Murrell, Richard A. Wittal, Dédée F. Murrell, Benjamin S. Daniel   +13 more
wiley   +1 more source

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms [PDF]

, 2014
The transforming JAK2V617F kinase is frequently associated with myeloproliferative neoplasms (MPNs) and thought to be instrumental for the overproduction of myeloid lineage cells.
Chowdary, Tirumala K., Deshpande, Anagha, Griffin, James D., Ray, Arghya, Reddy, Mamatha M., Sattler, Martin, Schade, Georg O.M.   +6 more
core   +1 more source

Successful Treatment of Coexisting Alopecia Areata and Bullous Pemphigoid With Dupilumab: A Case Report

JEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) and bullous pemphigoid (BP) are distinct autoimmune diseases, but growing evidence points to overlapping immune pathways. We present a rare case of a 71‐year‐old woman with concurrent AA and BP. She initially presented with 10 months of progressive scalp and body hair loss (Severity of Alopecia Tool [SALT] ~ 80) and nail ...
Anna Brinks, Carli Needle, Caitlin Kearney, Prince Adotama, Kenneth Grossman, Jerry Shapiro, Kristen Lo Sicco   +6 more
wiley   +1 more source

Ruxolitinib as an emerging treatment in myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy, 2013
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA Abstract: Essential thrombocythemia, polycythemia vera, and myelofibrosis belong to the class of Bcr-Abl negative hematologic neoplasms, which arise in part from varying Janus kinase-2 (JAK2 ...
Robyn M. Emanuel, Ruben A. Mesa, Holly L. Geyer   +2 more
openaire   +4 more sources

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Haematologica, 2016
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera.
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian   +23 more
doaj   +1 more source

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report [PDF]

, 2012
Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia.
COLOMBA, Claudia, LALICATA, Francesco, Rubino, R, Siracusa, L, TITONE LANZA DI SCALEA, Lucina, Tolomeo, M., Trizzino, M   +6 more
core   +2 more sources

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

Comparative evaluation of supervised and unsupervised deep learning strategies for denoising hyperpolarized 129Xe lung MRI

Magnetic Resonance in Medicine, EarlyView.
Abstract Purpose Reduced signal‐to‐noise ratio (SNR) in hyperpolarized 129Xe MR images can affect accurate quantification for research and diagnostic evaluations. Thus, this study explores the application of supervised deep learning (DL) denoising, traditional (Trad) and Noise2Noise (N2N) and unsupervised Noise2void (N2V) approaches for 129Xe MR ...
Abdullah S. Bdaiwi, Matthew M. Willmering, Riaz Hussain, Erik Hysinger, Jason C. Woods, Laura L. Walkup, Zackary I. Cleveland   +6 more
wiley   +1 more source